Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 13/20 | 0.63 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.53 |
| ▸ | AGT | P01019 | 2/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670077 | 1.00 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL1259493 | 1.00 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL8140438 | 0.95 | AGTR1 (0.56) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL29205122 | 0.93 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL29205124 | 0.93 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL4092523 | 0.93 | AGTR1 (0.59) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL4154512 | 0.92 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL2913 | 0.92 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL12894045 | 0.92 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL1891052 | 0.92 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6AGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104151199-A | Method for synthesizing valsartan | SUZHOU HEALTH COLLEGE | 2014-11-19 | — | — | CN | disclosed |
| US-8492577-B2 | Process for preparation of valsartan intermediate | HETERO RESEARCH FOUNDATION (IN) | 2013-07-23 | — | — | US | disclosed |
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-09-29 | — | — | US | disclosed |
| US-7880015-B2 | treating N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester with oxalic acid to produce N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester oxalate, treating intermediate with a base and vlaeryl chloride , deprotecting; Valsartan product | AUROBINDO PHARMA LTD. (IN) | 2011-02-01 | — | — | US | disclosed |
| US-7880015-B2 | treating N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester with oxalic acid to produce N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester oxalate, treating intermediate with a base and vlaeryl chloride , deprotecting; Valsartan product | AUROBINDO PHARMA LTD. (IN) | 2011-02-01 | — | — | US | disclosed |
| EP-2260018-A2 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | Hetero Research Foundation (IN) | 2010-12-15 | — | — | EP | disclosed |
| US-20090281326-A1 | Process For the Preparation of Angiotensin II Antagonist | AUROBINDO PHARMA LTD (IN) | 2009-11-12 | — | — | US | disclosed |
| US-20090281326-A1 | Process For the Preparation of Angiotensin II Antagonist | AUROBINDO PHARMA LTD (IN) | 2009-11-12 | — | — | US | disclosed |
| WO-2009125416-A2 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281326-A1 | Process For the Preparation of Angiotensin II Antagonist | REN, VCL, PTMS | AGTR1 7/4885LTB4R2 1367/4885ABCB11 493/4885 |
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | REN, AGT, ACE | AGTR1 6/4885LTB4R2 2598/4885ABCB11 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.